United States-Abraham Accords Cooperation and Security Act of 2025

This bill would create a new Abraham Accords Office inside the Food and Drug Administration (FDA). The office would be set up in a country that has signed the Abraham Accords, chosen with input from those governments and U.S. diplomatic and security staff. It must be opened within two years of the law taking effect.

Once open, the office would help partner countries strengthen and align rules for products the FDA oversees, including medical products and good manufacturing practices. It would also share information about U.S. approval pathways, and help connect the FDA with researchers, developers, and manufacturers in those countries. The office may take on other tasks the Secretary finds necessary. A national security safeguard says nothing in the bill requires actions that go against federal national security advice. “Abraham Accords country” means a nation the State Department says signed the Abraham Accords Declaration.

• Who is affected: FDA staff; regulators and interested parties (like manufacturers and researchers) in Abraham Accords countries.
• What changes: A new FDA office abroad to provide technical help, share regulatory information, and facilitate feedback on research, development, and manufacturing of FDA‑regulated products, including manufacturing quality practices.
• When: Office must be established within 2 years; a progress report to Congress is due within 3 years, including what assistance was provided and recommendations to improve coordination.